Unlike animals, plants do not possess an adaptive immune system with antibodies or T cells to fight viral infections. Instead ...

Fungal infections are on the rise globally. According to a study by the Manchester Fungal Infection Group, in 2022, ...

The Series B funds will support the launch of a Phase I/II clinical trial for AIR-001 to advance its RNA editing pipeline.

AIRNA, a transatlantic RNA editing biotech, is prepping to launch its lead asset into clinical trials with fuel from a $155 ...

Airna will use the Series B round to launch a Phase 1/2 trial of its lead program for alpha-1 antitrypsin deficiency, a ...

Before a prostate biopsy is performed, various preliminary screening procedures are typically conducted. These include a ...

RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with ...

Aqemia announces it is broadening and accelerating its computational platform to target RNAs using its physics-enabled ...

AIRNA’s lead candidate AIR-001 works by correcting the most common pathologic mutation driving the rare disease alpha-1 ...

Korro Bio's OPERA platform offers precise RNA editing for genetic diseases like Alpha-1 antitrypsin deficiency. Learn more on ...

The Republic aims to strengthen its RNA capabilities by providing a platform for key institutions here to collaborate. Read ...

There is an urgent need for precision immunotherapy strategies that simultaneously target both tumor cells and immune cells ...